(Q35917412)

11 August 2017

1 reference

title

Nevirapine in the treatment of HIV. (English)

1 reference

11 August 2017

1 reference

Ana Milinkovic

1

0 references

author name string

Esteban Martínez

series ordinal

2

1 reference

11 August 2017

publication date

1 June 2004

1 reference

Expert Review of Anti-infective Therapy

11 August 2017

published in

1 reference

11 August 2017

volume

2

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

367-373

1 reference

The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Pharmacokinetic Drug Interactions with Nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Impact of nevirapine on lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Defining the toxicity profile of nevirapine and other antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

A compromise strategy for patients with multiple drug failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.367

21 January 2018

Identifiers

DOI

10.1586/14787210.2.3.367

1 reference

11 August 2017

1 reference